Intergroupe Francophone De Cancerologie Thoracique

This study tests whether the targeted drug tepotinib works better than standard treatments for people with advanced non-small cell lung cancer that has a specific MET gene change. About 133 adults whose cancer worsened after initial therapy will be randomly assigned to receive te…

This study tests a drug called ivonescimab in 38 people with pleural mesothelioma whose cancer returned after immunotherapy and chemotherapy. The drug is given every 3 weeks for up to 2 years. The main goal is to see if it can stop the cancer from growing for at least 12 weeks.

This study is for elderly or less healthy patients with stage III lung cancer that cannot be removed by surgery. It tests whether adding immunotherapy to chemotherapy before radiation therapy can help control the cancer longer. About 152 participants will be randomly assigned to …

This phase 3 trial tests whether tarlatamab works better than standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC) that has already been treated. About 129 adults with lung or digestive system NEC will receive either tarlatamab or chemo chosen by their do…